Veterans struggling with invisible wounds from war could soon get breakthrough help from mind-altering drugs. A new bipartisan bill promises $30 million a year to set up special centers at Veterans Affairs facilities. These spots would test treatments like psilocybin and MDMA to ease PTSD and other issues. Lawmakers say this push could save lives as research shows real hope.
The Innovative Therapies Centers of Excellence Act aims to change how the VA handles mental health care. Senators Ruben Gallego from Arizona and David McCormick from Pennsylvania introduced it this week. The bill would require the VA to pick five medical facilities and turn them into hubs for psychedelic research and treatment.
These centers would focus on substances such as psilocybin from magic mushrooms, MDMA known as ecstasy, and ibogaine from a plant root. Veterans could access guided therapy sessions under doctor supervision. The funding starts at $30 million each year for five years to cover studies, training, and care.
Lawmakers stress that current treatments fall short for many vets. Over 20 veterans die by suicide every day, according to VA data from 2024. This bill seeks to fill that gap with innovative options backed by early science.
One key part calls for the VA secretary to report progress to Congress yearly. That ensures accountability and quick fixes if needed.
Bipartisan Support Builds Momentum in Congress
Support crosses party lines, showing rare unity on a tough topic. Gallego, a Democrat and Marine Corps veteran, teams up with McCormick, a Republican and former Army Ranger. They filed the Senate version on March 9, 2026, right after similar efforts in the House.
In the House, Representatives Lou Correa from California and Jack Bergman from Michigan led the charge last year. Their bill, introduced in April 2025, mirrors the Senate one almost exactly. It has not moved forward yet, but backers hope the fresh Senate push lights a fire.
The Congressional Psychedelics Advancing Therapies Caucus, co-chaired by Correa and Bergman, drives this work. Members from both parties see psychedelics as a tool to help vets heal faster. Bergman, a retired Marine general, often shares stories from troops who swear by these therapies.
This teamwork stands out in a divided Congress. It could speed up passage if leaders prioritize veterans’ needs.
Early Research Shows Promise for Psychedelic Treatments
Science backs the excitement around these drugs for mental health. A small study in January 2024 found ibogaine cut PTSD symptoms in veterans right away. Researchers at Stanford gave it to 30 special ops vets with traumatic brain injuries. Functioning improved by 88% on average, and depression scores dropped sharply.
MDMA has stronger data too. In December 2024, the VA funded its first big study on MDMA-assisted therapy for PTSD and alcohol use. Phase 3 trials earlier showed it reduced symptoms in 67% of patients, compared to just 32% on placebo. That comes from data released by the Multidisciplinary Association for Psychedelic Studies in 2023.
Psilocybin looks good for depression and anxiety, per a 2025 review in the Journal of Psychopharmacology. It helped 80% of users in small trials feel less anxious after one session. But PTSD-specific research lags, with only a few ongoing VA pilots.
To break down the options, here is a simple table of key substances and their potential benefits based on recent studies:
| Substance | Main Use in Research | Key Finding | Study Year |
|---|---|---|---|
| Psilocybin | Depression, Anxiety | Improved mood in 80% of participants | 2025 |
| MDMA | PTSD, Trauma | Symptom reduction in 67% of cases | 2023 |
| Ibogaine | TBI, PTSD | 88% better functioning immediately | 2024 |
Experts warn more large-scale trials are needed. Side effects like nausea or bad trips happen, but guided sessions keep risks low.
Veterans in programs report feeling reborn. One vet from a 2025 ayahuasca retreat said it ended years of nightmares. Such stories fuel the bill’s drive.
Trump Administration Backs Psychedelic Expansion
The White House adds weight to this effort. Officials under President Trump push for wider access to these therapies. In February 2026, Health and Human Services Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan the administration is “very anxious” to approve psychedelic treatments fast.
Kennedy highlighted vets’ needs during a January 2026 speech. He noted how Schedule I status blocks research, but reforms could change that. The FDA already fast-tracks some psychedelic drugs, though a psilocybin bid for depression stalled in early 2026.
This aligns with VA moves. By November 2025, the department expanded MDMA trials to more sites. Officials say early results match private studies, with vets showing lasting gains in therapy.
Critics worry about safety and addiction risks. But supporters point to low abuse rates in controlled settings. The admin’s stance could sway skeptics and boost the bill.
State actions help too. Utah passed a law in March 2026 for clinical trials on psychedelics for vets’ PTSD. That sets a model for federal steps.
As research grows, families of vets watch closely. Better options mean fewer lost to despair. This bill could mark a turning point in how America cares for its heroes.
Lawmakers and experts agree the time is now. With solid data and top-level support, psychedelic therapy for veterans feels closer than ever. It offers real hope against the mental health crisis hitting troops hard.
